Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we investigated the effects of tofacitinib on patient-reported outcomes (PRO) in patients with active RA.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Exp. Rheumatol.

Title: Clinical and experimental rheumatology

ISSN: 0392-856X

ISSN (Print): 0392-856X

Publication date (Electronic): May 10 2016

Volume: 34

Issue: 3

Affiliations

[1 ] Pfizer Inc, Groton, CT, USA. gene.wallenstein@pfizer.com.

[2 ] Pfizer Inc, Groton, CT, USA.

[3 ] Metroplex Clinical Research Center, Dallas, TX, USA.

[4 ] University of Genoa, Italy.

[5 ] Stanford University, Stanford, CA, USA.

[6 ] Hospital Clinico Universitario, Santiago de Compostela, Spain.

[7 ] Albany Medical College, Albany, NY, USA.

[8 ] Seoul National University College of Medicine, Seoul, Republic of Korea.

[9 ] Instituto Nacional de Ciencias Médicas y Nutrición-Salvador Zubirán, Mexico City, Mexico.

Article

Publisher Item ID: 9525

PubMed ID: 27156561

SO-VID: c0c99d90-d11b-4108-b3f4-8a97680e286d

History

Data availability:

Comments

Comment on this article

Cited by 18

See all cited by